Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28481584 | 1.00 | PPARD (0.33) | PPARDPPARAPPARGALDH1A1MAPT | |
| SCHEMBL28481585 | 1.00 | PPARD (0.33) | PPARDPPARAPPARGALDH1A1MAPT | |
| SCHEMBL29092256 | 1.00 | PPARD (0.33) | PPARDPPARAPPARGALDH1A1MAPT | |
| SCHEMBL29981902 | 1.00 | PPARD (0.33) | PPARDPPARAPPARGALDH1A1MAPT | |
| SCHEMBL21382331 | 0.88 | PPARD (0.33) | PPARDPPARAPPARG | |
| SCHEMBL21384817 | 0.88 | PPARD (0.33) | PPARDPPARAPPARG | |
| SCHEMBL21382334 | 0.88 | PPARD (0.33) | PPARDPPARAPPARG | |
| SCHEMBL29981877 | 0.87 | — | — | |
| SCHEMBL29092715 | 0.87 | — | — | |
| SCHEMBL29092716 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.